ライフサイエンスコーパス: we selected

1 We selected 12 diverse molecular targets for Affimer selectio

2 We selected 121 live-born singletons after KT (Italian study

3 We selected 13 up-regulated HdT-exclusive genes to validate b

4 Here, we selected 18 Myc-regulated genes from published studies of

5 We selected 2 common variants (rs3918226 in NOS3 and rs769238

6 We selected 20 bacterial species with 25 patterns of acquired

7 Using convenience and probability sampling, we selected 23 health facilities, 36 vaccinators, and 336 car

8 We selected 24 e-cigarette flavors from the top selling dispo

9 Through prioritization and stringent selection criteria, we selected 24 SNPs for further genotyping in 1,516 breast ca

10 Between Jan 20, 2010, and Sept 13, 2012, we selected 241 cases, for which PMCTA was successful in 204

11 For the longitudinal neuroimaging analysis, we selected 27 patients with PD-ICB with available neuroimagi

12 isease-associated variants might activate cryptic splicing, we selected 458 pathogenic variants and 348 variants of uncer

13 We selected 55 cactus species from the Americas, all geo-refe

14 We selected 6 brains from confirmed cases of human sporadic C

15 We selected 7,734 SNPs for linkage mapping, resulting in 27 l

16 For this exploratory retrospective study, we selected a cohort of patients with newly diagnosed or rela

17 We selected a high-affinity monkey cross-reactive anti-CLL-1

18 g Resource and Biobank Core (CPROBE) cohort of 1235 adults, we selected a panel of 214 36 with stage 1 or 2 CKD, 99 with

19 Here, we selected a range of slow-release electron donor/chemical r

20 On the basis of potency and bioavailability, we selected a small molecule, SR-18292, that reduces blood gl

21 ar period in 13 high-volume centers for esophageal surgery, we selected a study group of 334 patients (31.6%) that fulfil

22 We selected adult subjects with an estimated glomerular filtr

23 For our analysis, we selected all meta-analyses that included a minimum of 5 or

24 Using the cellular distribution insights, we selected an amphiphilic surface ligand-coated AuNP that ta

25 We selected articles that presented risk estimates for indivi

26 Here we selected broadly neutralizing nanobodies by phage display

27 sent the potential diagnostic applications of our approach, we selected carbon nanotubes (CNT)-based inkjet-printed dispo

28 From the UK adult kidney transplant waiting list, we selected crossmatch positive living donor HLAi kidney tran

29 In December of 2013, we selected dialysis facilities with either low transplant re

30 We selected for conversion in multiple different positions of

31 Based on these parameters we selected four mammalian and two mosquito cell lines, and f

32 We selected four variants (Q203F, T538F, I548F, and M629P) fo

33 the profiles from all methods following a simple strategy: we selected genes that were confirmed as differentially expre

34 We selected large panels of 50 and 100 Envs either to charact

35 We selected lung and breast cancer cell lines for the ability

36 We selected one of the catalytic subunits of the subfamily I,

37 We selected panels to represent the diversity of bnAb neutral

38 In this study we selected patients admitted with septic shock and treated f

39 We selected Scots pine (Pinus sylvestris L.) as a model speci

40 Following standard procedures used in pathology, we selected small fresh frozen uterine tissue samples to inve

41 We selected studies that compared treatment vs nontreatment o

42 We selected the 12 most similar hospitals in terms of structu

43 From the 137 drugs included in the FDA table, we selected the 22 oncology drugs with required genetic testi

44 We selected the BRF1 gene, which encodes an RNA polymerase II

45 In this study, we selected the somatostatin receptor imaging agent DOTATOC a

46 o describe the mechanisms of electrochemical oxidation, and we selected the two methods of ABTS (2,2'-azinobis-(3-ethylbe

47 In this study, we selected thermally stable ECs of type 1 PV (PV-1).

48 me analysis and liquid chromatography-tandem MS (LC-MS/MS), we selected three high abundance peptide markers of the KPC p

49 Patients and Methods Using the National Cancer Database, we selected two cohorts of patients with nonmetastatic NSCLC

50 We selected variants, reported in the largest GWAS to date, a